The Mitogen Activated Protein Kinase Kinase Kinase Kinase pipeline drugs market research report outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mitogen Activated Protein Kinase Kinase Kinase Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Undisclosed, and Central Nervous System which include the indications Solid Tumor, Unspecified Cancer, Unspecified, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The Mitogen Activated Protein Kinase Kinase Kinase Kinase pipeline targets constitutes close to 31 molecules. Out of which, approximately 28 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 5, 4, 2, 13, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Mitogen Activated Protein Kinase Kinase Kinase Kinase overview
Mitogen-activated protein kinase kinase kinase (MAPKKK) is a serine/threonine-specific protein kinase that acts on MAP kinase kinase. MAP kinase kinase then activates MAP kinase. MAPKKKs are characterized by the MAP kinases they activate. MAPKs are activated by phosphorylation of both threonine and tyrosine residues within a signature T–X–Y motif located in the activation loop of the kinase. This is catalyzed by a dual-specificity MAPK kinase (MKK or MEK).
For a complete picture of Mitogen Activated Protein Kinase Kinase Kinase Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
